Yahoo
Mexico - Delayed Quote MXN

Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX)

15.49 +0.38 (+2.51%)
At close: November 4 at 2:59:55 PM CST
Chart Range Bar
Loading chart for LABB.MX
  • Previous Close 15.11
  • Open 15.19
  • Bid 15.47 x 50000
  • Ask 15.53 x 194200
  • Day's Range 15.11 - 15.62
  • 52 Week Range 12.22 - 19.48
  • Volume 2,740,978
  • Avg. Volume 3,662,821
  • Market Cap (intraday) 15.145B
  • Beta (5Y Monthly) -0.01
  • PE Ratio (TTM) 9.11
  • EPS (TTM) 1.70
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield 0.80 (5.16%)
  • Ex-Dividend Date Sep 29, 2026
  • 1y Target Est 21.33

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

www.genommalab.com

1,801

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is S&P/BMV IPC (^MXX) .

YTD Return

LABB.MX
9.93%
S&P/BMV IPC (^MXX)
10.13%

1-Year Return

LABB.MX
8.08%
S&P/BMV IPC (^MXX)
13.51%

3-Year Return

LABB.MX
25.44%
S&P/BMV IPC (^MXX)
38.14%

5-Year Return

LABB.MX
2.36%
S&P/BMV IPC (^MXX)
36.52%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 4.5B
Earnings 514.9M
Profit Margin 11.45%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
1B
2B
3B
4B
8.0%
9.0%
10.0%
11.0%

Analyst Insights

View More

Analyst Price Targets

16.00
21.33 Average
15.49 Current
29.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.00%

  • Return on Assets (ttm)

    8.74%

  • Return on Equity (ttm)

    14.72%

  • Revenue (ttm)

    17.1B

  • Net Income Avi to Common (ttm)

    1.71B

  • Diluted EPS (ttm)

    1.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.74B

  • Total Debt/Equity (mrq)

    65.89%

  • Levered Free Cash Flow (ttm)

    551.46M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: